Full Product Name
CLN5 siRNA (Human)
Product Synonym Names
Ceroid-lipofuscinosis neuronal protein 5; Protein CLN5
Product Gene Name
CLN5 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for O75503
Specificity
CLN5 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human CLN5 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of CLN5 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
CLN5 sirna
siRNA to inhibit CLN5 expression using RNA interference
Applications Tested/Suitable for CLN5 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for CLN5. It may not necessarily be applicable to this product.
NCBI Accession #
NP_006484.1
[Other Products]
NCBI GenBank Nucleotide #
NM_006493.2
[Other Products]
UniProt Primary Accession #
O75503
[Other Products]
UniProt Secondary Accession #
B3KQK7[Other Products]
UniProt Related Accession #
O75503[Other Products]
Molecular Weight
41,497 Da
NCBI Official Full Name
ceroid-lipofuscinosis neuronal protein 5
NCBI Official Synonym Full Names
ceroid-lipofuscinosis, neuronal 5
NCBI Official Symbol
CLN5 [Similar Products]
NCBI Official Synonym Symbols
NCL
[Similar Products]
NCBI Protein Information
ceroid-lipofuscinosis neuronal protein 5
UniProt Protein Name
Ceroid-lipofuscinosis neuronal protein 5
Protein Family
Cln5-like protein
UniProt Gene Name
CLN5 [Similar Products]
UniProt Synonym Gene Names
Protein CLN5 [Similar Products]
UniProt Entry Name
CLN5_HUMAN
NCBI Summary for CLN5
This gene is one of eight which have been associated with neuronal ceroid lipofuscinoses (NCL). Also referred to as Batten disease, NCL comprises a class of autosomal recessive, neurodegenerative disorders affecting children. The genes responsible likely encode proteins involved in the degradation of post-translationally modified proteins in lysosomes. The primary defect in NCL disorders is thought to be associated with lysosomal storage function.[provided by RefSeq, Oct 2008]
UniProt Comments for CLN5
CLN5: Defects in CLN5 are the cause of neuronal ceroid lipofuscinosis type 5 (CLN5); also known as Finnish variant late-infantile neuronal ceroid lipofuscinosis (vLINCL). A form of neuronal ceroid lipofuscinosis. Neuronal ceroid lipofuscinoses are progressive neurodegenerative, lysosomal storage diseases characterized by intracellular accumulation of autofluorescent liposomal material, and clinically by seizures, dementia, visual loss, and/or cerebral atrophy. The lipopigment patterns observed most often in neuronal ceroid lipofuscinosis type 5 comprise mixed combinations of granular, curvilinear, and fingerprint profiles. Belongs to the CLN5 family.
Protein type: Membrane protein, integral
Chromosomal Location of Human Ortholog: 13q21.1-q32
Cellular Component: Golgi apparatus; endoplasmic reticulum; lysosomal membrane; lysosome; perinuclear region of cytoplasm; integral to membrane
Molecular Function: mannose binding; protein binding
Biological Process: signal peptide processing; neurogenesis; lysosomal lumen acidification; protein catabolic process; brain development; neuron maturation
Disease: Ceroid Lipofuscinosis, Neuronal, 5
Research Articles on CLN5
1. There are functional differences in various N-glycosylation sites of CLN5 which affect folding, trafficking, and lysosomal function of CLN5.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
